Literature DB >> 6323952

Biphasic regulation of the gonadotropin-releasing hormone receptor by receptor microaggregation and intracellular Ca2+ levels.

P M Conn, D C Rogers, S G Seay.   

Abstract

In the present work we show that Ca2+ is both necessary and sufficient to evoke homologous up-regulation of the gonadotropin-releasing hormone (GnRH) receptor. Extracellular Ca2+ as well as RNA and protein synthesis were required for this event, and it was blocked by Ca2+ ion channel blockers. Drugs which stimulated increased intracellular Ca2+ levels also stimulated receptor up-regulation and enhanced responsiveness even in the absence of added GnRH. Such drugs were effective below the concentrations needed to evoke luteinizing hormone (LH) release, suggesting that enhanced levels of Ca2+ ion, rather than LH depletion, is the responsible agent. A GnRH antagonist did not evoke up- or down-regulation; however, a conjugate of this antagonist, which stimulated microaggregation of the GnRH receptor, also stimulated these biphasic actions. In contrast to up-regulation, down-regulation of the GnRH receptor appears to be Ca2+-independent and does not require RNA or protein synthesis. These data are consistent with a model in which microaggregation of the GnRH receptor is the final step in common to a branched pathway consisting of Ca2+-dependent (LH release, enhanced sensitivity, up-regulation) and Ca2+-independent (desensitization, down-regulation) events.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6323952

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  11 in total

1.  A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients.

Authors:  Chay Ngee Lim; Ahmed Hamed Salem
Journal:  Clin Pharmacokinet       Date:  2015-09       Impact factor: 6.447

2.  Comparison of single-agent androgen suppression for advanced prostate cancer.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2005

3.  Homologous upregulation of GnRH receptor mRNA by continuous GnRH in cultured rat pituitary cells.

Authors:  M Cheon; D Park; K Kim; S D Park; K Ryu
Journal:  Endocrine       Date:  1999-08       Impact factor: 3.633

4.  Androgen deprivation therapy in the treatment of advanced prostate cancer.

Authors:  Mark A Perlmutter; Herbert Lepor
Journal:  Rev Urol       Date:  2007

5.  Neuroendocrineimmunology (NEI) at the turn of the century: towards a molecular understanding of basic mechanisms and implications for reproductive physiopathology.

Authors:  B Marchetti; M C Morale; F Gallo; N Batticane; Z Farinella; M Cioni
Journal:  Endocrine       Date:  1995-12       Impact factor: 3.633

6.  Regulation of pituitary gonadotropin-releasing hormone receptors by pulsatile gonadotropin-releasing hormone injections in male rats. Modulation by testosterone.

Authors:  A Garcia; M Schiff; J C Marshall
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

7.  Frequency specificity in intercellular communication. Influence of patterns of periodic signaling on target cell responsiveness.

Authors:  Y Li; A Goldbeter
Journal:  Biophys J       Date:  1989-01       Impact factor: 4.033

8.  Alpha-fetoprotein controls female fertility and prenatal development of the gonadotropin-releasing hormone pathway through an antiestrogenic action.

Authors:  Christelle De Mees; Jean-François Laes; Julie Bakker; Johan Smitz; Benoît Hennuy; Pascale Van Vooren; Philippe Gabant; Josiane Szpirer; Claude Szpirer
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

9.  A mathematical model for LH release in response to continuous and pulsatile exposure of gonadotrophs to GnRH.

Authors:  Talitha M Washington; J Joseph Blum; Michael C Reed; P Michael Conn
Journal:  Theor Biol Med Model       Date:  2004-09-24       Impact factor: 2.432

10.  Leuprorelin depot injection: patient considerations in the management of prostatic cancer.

Authors:  Zinelabidine Abouelfadel; E David Crawford
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.